{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:10:07Z","timestamp":1784952607497,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012643","name":"Ohio Lions Eye Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012643","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jconrel.2020.01.036","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T20:36:39Z","timestamp":1579725399000},"page":"442-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Injectable biodegradable bi-layered capsule for sustained delivery of bevacizumab in treating wet age-related macular degeneration"],"prefix":"10.1016","volume":"320","author":[{"given":"Pengfei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Chaparro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton T.","family":"Cuddington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre F.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Ohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Lannutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1739-0263","authenticated-orcid":false,"given":"Katelyn E.","family":"Swindle-Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jconrel.2020.01.036_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/gb-2005-6-2-209","article-title":"The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease","volume":"6","author":"Holmes","year":"2005","journal-title":"Genome Biol."},{"issue":"12","key":"10.1016\/j.jconrel.2020.01.036_bb0010","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-Angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2020.01.036_bb0015","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1046\/j.1523-1755.1999.00610.x","article-title":"Role of vascular endothelial growth factor in the regulation of angiogenesis","volume":"56","author":"Ferrara","year":"1999","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.jconrel.2020.01.036_bb0020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.jconrel.2020.01.036_bb0025","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2174\/138945010791591395","article-title":"Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy","volume":"11","author":"Niu","year":"2010","journal-title":"Curr. Drug Targets"},{"issue":"20","key":"10.1016\/j.jconrel.2020.01.036_bb0030","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2020.01.036_bb0035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jconrel.2015.09.065","article-title":"Delivery strategies for treatment of age-related ocular diseases: from a biological understanding to biomaterial solutions","volume":"219","author":"Delplace","year":"2015","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2020.01.036_bb0040","first-page":"585","article-title":"Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration","volume":"13","author":"Ohr","year":"2012","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.jconrel.2020.01.036_bb0045","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment\u2013a review","volume":"100","author":"H\u00e5rd","year":"2011","journal-title":"Acta Paediatr."},{"issue":"3","key":"10.1016\/j.jconrel.2020.01.036_bb0050","first-page":"434","article-title":"Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor trap-eye)","volume":"32","author":"Stewart","year":"2012","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.jconrel.2020.01.036_bb0055","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ICU.0b013e328338679a","article-title":"Complications of intravitreal injections","volume":"21","author":"Sampat","year":"2010","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"11","key":"10.1016\/j.jconrel.2020.01.036_bb0060","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00347-016-0275-z","article-title":"Compliance von Patienten mit altersabh\u00e4ngiger Makuladegeneration unter Anti-VEGF-Therapie","volume":"113","author":"Heimes","year":"2016","journal-title":"Der Ophthalmologe"},{"issue":"2","key":"10.1016\/j.jconrel.2020.01.036_bb0065","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2016.10.015","article-title":"Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins","volume":"22","author":"Radhakrishnan","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2020.01.036_bb0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2018.06.031","article-title":"Polymer-based carriers for ophthalmic drug delivery","volume":"285","author":"Imperiale","year":"2018","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.jconrel.2020.01.036_bb0075","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11095-010-0159-x","article-title":"Biodegradable implants for sustained drug release in the eye","volume":"27","author":"Lee","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.01.036_bb0080","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2014.06.043","article-title":"Ocular delivery of macromolecules","volume":"190","author":"Kim","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.01.036_bb0085","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1590\/S1984-82502010000300024","article-title":"Implants as drug delivery devices for the treatment of eye diseases","volume":"46","author":"Silva","year":"2010","journal-title":"Brazilian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.01.036_bb0090","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874364101206010054","article-title":"Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration","volume":"6","author":"Li","year":"2012","journal-title":"Open Ophthalmol."},{"issue":"1","key":"10.1016\/j.jconrel.2020.01.036_bb0095","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1038\/s41598-017-03959-4","article-title":"A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles","volume":"7","author":"Sousa","year":"2017","journal-title":"Sci. Rep."},{"issue":"24","key":"10.1016\/j.jconrel.2020.01.036_bb0100","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/S0142-9612(01)00172-7","article-title":"Retinal pigment epithelium engineering using synthetic biodegradable polymers","volume":"22","author":"Lu","year":"2001","journal-title":"Biomaterials"},{"issue":"9","key":"10.1016\/j.jconrel.2020.01.036_bb0105","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.biomaterials.2005.09.019","article-title":"The in vivo degradation, absorption and excretion of PCL-based implant","volume":"27","author":"Sun","year":"2006","journal-title":"Biomaterials"},{"issue":"8\u20139","key":"10.1016\/j.jconrel.2020.01.036_bb0110","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.progpolymsci.2007.05.017","article-title":"Biodegradable polymers as biomaterials","volume":"32","author":"Nair","year":"2007","journal-title":"Prog. Polym. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2020.01.036_bb0115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/jop.2012.0152","article-title":"Ocular biocompatibility and structural integrity of micro-and nanostructured poly (caprolactone) films","volume":"29","author":"Bernards","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2020.01.036_bb0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jconrel.2017.11.008","article-title":"Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent","volume":"269","author":"Kim","year":"2018","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2020.01.036_bb0125","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1167\/iovs.15-17757","article-title":"In vitro and in vivo sustained zero-order delivery of rapamycin (Sirolimus) from a biodegradable intraocular DeviceSustained zero-order delivery of rapamycin","volume":"56","author":"Lance","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2020.01.036_bb0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1088\/0960-1317\/10\/1\/311","article-title":"Microengineering, Microfabrication technology for polycaprolactone, a biodegradable polymer","volume":"10","author":"Armani","year":"2000","journal-title":"J. Micromech. Microeng."},{"issue":"1","key":"10.1016\/j.jconrel.2020.01.036_bb0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0142-9612(01)00094-1","article-title":"In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant","volume":"23","author":"Mi","year":"2002","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2020.01.036_bb0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2009.09.004","article-title":"Biodegradation, biodistribution and toxicity of chitosan","volume":"62","author":"Kean","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"14","key":"10.1016\/j.jconrel.2020.01.036_bb0145","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1016\/j.biomaterials.2014.01.078","article-title":"Controlling chitosan-based encapsulation for protein and vaccine delivery","volume":"35","author":"Koppolu","year":"2014","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2020.01.036_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2006.04.017","article-title":"Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan\u2014a review","volume":"114","author":"George","year":"2006","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2020.01.036_bb0155","first-page":"1","article-title":"Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats","volume":"7","author":"Lu","year":"2014","journal-title":"Int. J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.jconrel.2020.01.036_bb0160","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/jbm.a.36424","article-title":"Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment","volume":"106","author":"Badiee","year":"2018","journal-title":"J. Biomed. Mater. Res. A"},{"issue":"32","key":"10.1016\/j.jconrel.2020.01.036_bb0165","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1002\/ange.200501500","article-title":"Stimuli-responsive controlled drug release from a hollow mesoporous silica sphere\/polyelectrolyte multilayer core\u2013shell structure","volume":"117","author":"Zhu","year":"2005","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"1","key":"10.1016\/j.jconrel.2020.01.036_bb0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.carbpol.2013.04.060","article-title":"Fabrication of sonicated chitosan nanofiber mat with enlarged porosity for use as hemostatic materials","volume":"97","author":"Gu","year":"2013","journal-title":"Carbohydr. Polym."},{"issue":"26","key":"10.1016\/j.jconrel.2020.01.036_bb0175","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1039\/c0jm04502k","article-title":"Design, fabrication and characterization of PCL electrospun scaffolds\u2014a review","volume":"21","author":"Cipitria","year":"2011","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.jconrel.2020.01.036_bb0180","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.msec.2019.01.095","article-title":"Sintered Electrospun Polycaprolactone for Controlled Model Drug Delivery","volume":"99","author":"Chaparro","year":"2019","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"issue":"4","key":"10.1016\/j.jconrel.2020.01.036_bb0185","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.actbio.2010.11.022","article-title":"Modulation of embryonic mesenchymal progenitor cell differentiation via control over pure mechanical modulus in electrospun nanofibers","volume":"7","author":"Nam","year":"2011","journal-title":"Acta Biomater."},{"issue":"26","key":"10.1016\/j.jconrel.2020.01.036_bb0190","doi-asserted-by":"crossref","first-page":"47731","DOI":"10.1002\/app.47731","article-title":"Sintered electrospun poly(\u025b-caprolactone)\u2013poly(ethylene terephthalate) for drug delivery","volume":"136","author":"Chaparro","year":"2019","journal-title":"J. Appl. Polym. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2020.01.036_bb0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jcis.2004.02.001","article-title":"FTIR study of polycaprolactone chain organization at interfaces","volume":"273","author":"Elzein","year":"2004","journal-title":"J. Colloid Interface Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2020.01.036_bb0200","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0013-4686(02)00812-5","article-title":"FTIR studies of chitosan acetate based polymer electrolytes","volume":"48","author":"Osman","year":"2003","journal-title":"Electrochim. Acta"},{"issue":"10","key":"10.1016\/j.jconrel.2020.01.036_bb0205","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1021\/nl302747y","article-title":"Nanostructured thin film polymer devices for constant-rate protein delivery","volume":"12","author":"Bernards","year":"2012","journal-title":"Nano Lett."},{"issue":"12","key":"10.1016\/j.jconrel.2020.01.036_bb0210","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1021\/mp400487f","article-title":"Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench Technology for Sustained Delivery of bevacizumab","volume":"10","author":"Yandrapu","year":"2013","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.jconrel.2020.01.036_bb0215","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/mp300716t","article-title":"Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.jconrel.2020.01.036_bb0220","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1002\/jbm.a.35446","article-title":"Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment","volume":"103","author":"Varshochian","year":"2015","journal-title":"J. Biomed. Mater. Res. A"},{"issue":"47","key":"10.1016\/j.jconrel.2020.01.036_bb0225","doi-asserted-by":"crossref","first-page":"16754","DOI":"10.1073\/pnas.1419576111","article-title":"Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-\u03b1","volume":"111","author":"Sur","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.jconrel.2020.01.036_bb0230","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2015.05.279","article-title":"Novel biodegradable polyesteramide microspheres for controlled drug delivery in ophthalmology","volume":"211","author":"Andr\u00e9s-Guerrero","year":"2015","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2020.01.036_bb0235","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10856-007-3192-5","article-title":"In vitro biocompatibility of degradable biopolymers in cell line cultures from various ocular tissues: extraction studies","volume":"19","author":"Huhtala","year":"2008","journal-title":"J. Mater. Sci. Mater. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2020.01.036_bb0240","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1021\/acs.molpharmaceut.6b00335","article-title":"PLGA microparticles entrapping chitosan-based nanoparticles for the ocular delivery of ranibizumab","volume":"13","author":"Elsaid","year":"2016","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2020.01.036_bb0245","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nprot.2010.6","article-title":"In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract","volume":"5","author":"Arnaoutova","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2020.01.036_bb0250","article-title":"Endothelial cell tube formation assay for the in vitro study of angiogenesis","volume":"91","author":"DeCicco-Skinner","year":"2014","journal-title":"J. Vis. Exp."},{"issue":"8","key":"10.1016\/j.jconrel.2020.01.036_bb0255","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1167\/iovs.14-15349","article-title":"In Vivo and In Vitro Feasibility Studies of Intraocular Use of Polyethylene Glycol\u2013Based Synthetic Sealant to Close Retinal Breaks in Porcine and Rabbit Eyes","volume":"56","author":"Hoshi","year":"2015","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2020.01.036_bb0260","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.carbpol.2010.04.074","article-title":"Biomedical applications of chitin and chitosan based nanomaterials\u2014A short review","volume":"82","author":"Jayakumar","year":"2010","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2020.01.036_bb0265","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.msec.2015.09.102","article-title":"Determining the mechanical properties of electrospun poly-\u03b5-caprolactone (PCL) nanofibers using AFM and a novel fiber anchoring technique","volume":"59","author":"Baker","year":"2016","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"issue":"2","key":"10.1016\/j.jconrel.2020.01.036_bb0270","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0141-3910(98)00005-6","article-title":"Enzymatic degradation of radiation crosslinked poly (\u03b5\u2013caprolactone)","volume":"62","author":"Darwis","year":"1998","journal-title":"Polym. Degrad. Stab."},{"issue":"1","key":"10.1016\/j.jconrel.2020.01.036_bb0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2009.09.004","article-title":"Biodegradation, biodistribution and toxicity of chitosan","volume":"62","author":"Kean","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2020.01.036_bb0280","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0142-9612(98)00159-8","article-title":"Biodegradation and distribution of water-soluble chitosan in mice","volume":"20","author":"Onishi","year":"1999","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.jconrel.2020.01.036_bb0285","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1021\/bm060286l","article-title":"Stability improvement of electrospun chitosan nanofibrous membranes in neutral or weak basic aqueous solutions","volume":"7","author":"Sangsanoh","year":"2006","journal-title":"Biomacromolecules"},{"issue":"8","key":"10.1016\/j.jconrel.2020.01.036_bb0290","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.msec.2009.07.006","article-title":"Mechanical properties of electrospun collagen\u2013chitosan complex single fibers and membrane","volume":"29","author":"Chen","year":"2009","journal-title":"Mater. Sci. Eng. C"},{"issue":"8","key":"10.1016\/j.jconrel.2020.01.036_bb0295","doi-asserted-by":"crossref","first-page":"7855","DOI":"10.1016\/j.actbio.2013.04.025","article-title":"Chitosan microparticles for delivery of proteins to the retina","volume":"9","author":"Wassmer","year":"2013","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.jconrel.2020.01.036_bb0300","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/19420862.2015.1112477","article-title":"Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab","volume":"8","author":"Courtois","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2020.01.036_bb0305","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chroma.2014.04.027","article-title":"Capability measurement of size-exclusion chromatography with a light-scattering detection method in a stability study of bevacizumab using the process capability indices","volume":"1353","author":"Oliva","year":"2014","journal-title":"J. Chromatogr. A"},{"issue":"2","key":"10.1016\/j.jconrel.2020.01.036_bb0310","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1074\/jbc.M111.297697","article-title":"Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 fc","volume":"287","author":"Latypov","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.jconrel.2020.01.036_bb0315","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.iae.0000225354.92444.7a","article-title":"Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing","volume":"26","author":"Bakri","year":"2006","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.jconrel.2020.01.036_bb0320","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejps.2013.07.014","article-title":"The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments","volume":"50","author":"Varshochian","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.01.036_bb0325","first-page":"1043","article-title":"Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex\u00ae) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion","volume":"5","author":"Chan","year":"2011","journal-title":"Clin. Ophthalmol. (Auckland, NZ)"},{"issue":"5","key":"10.1016\/j.jconrel.2020.01.036_bb0330","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/jop.2012.0180","article-title":"A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis","volume":"29","author":"Arcinue","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2020.01.036_bb0335","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000342160","article-title":"Repeated intravitreal dexamethasone implant (Ozurdex\u00ae) for retinal vein occlusion","volume":"229","author":"Querques","year":"2013","journal-title":"Ophthalmologica"},{"issue":"5","key":"10.1016\/j.jconrel.2020.01.036_bb0340","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/jop.2013.0231","article-title":"Penetration force, geometry, and cutting profile of the novel and old Ozurdex needle: the MONO study","volume":"30","author":"Meyer","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2020.01.036_bb0345","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.jconrel.2020.01.036_bb0350","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2020.01.036_bb0355","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jpba.2010.12.027","article-title":"Effective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresis","volume":"55","author":"Li","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"8","key":"10.1016\/j.jconrel.2020.01.036_bb0360","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2020.01.036_bb0365","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijpharm.2009.12.046","article-title":"Iontophoretic transport of charged macromolecules across human sclera","volume":"388","author":"Chopra","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"18","key":"10.1016\/j.jconrel.2020.01.036_bb0370","doi-asserted-by":"crossref","first-page":"11597","DOI":"10.1021\/la2024605","article-title":"Measurements and theoretical interpretation of points of zero charge\/potential of BSA protein","volume":"27","author":"Salis","year":"2011","journal-title":"Langmuir"},{"issue":"4","key":"10.1016\/j.jconrel.2020.01.036_bb0375","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin\u00ae) for neovascular age-related macular degeneration","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg. Lasers Imaging"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920300559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920300559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:50:12Z","timestamp":1759161012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920300559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":75,"alternative-id":["S0168365920300559"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.01.036","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Injectable biodegradable bi-layered capsule for sustained delivery of bevacizumab in treating wet age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.01.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}